BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Price, Forecast & Analysis
NASDAQ:BCRX • US09058V1035
BCRX Key Statistics, Chart & Performance
The current stock price of BCRX is 6.76 USD. In the past month the price decreased by -5.72%. In the past year, price decreased by -25.3%.
BCRX Technical Analysis
BCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCRX. There are concerns on the financial health of BCRX while its profitability can be described as average.
BCRX Financial Highlights
Over the last trailing twelve months BCRX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 94.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCRX Forecast & Estimates
15 analysts have analysed BCRX and the average price target is 22.21 USD. This implies a price increase of 228.6% is expected in the next year compared to the current price of 6.76.
For the next year, analysts expect an EPS growth of 142.7% and a revenue growth 37.74% for BCRX
BCRX Ownership
BCRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCRX
Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
Company Info
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703 US
CEO: Jon P. Stonehouse
Employees: 580
Phone: 13026365400
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you describe the business of BIOCRYST PHARMACEUTICALS INC?
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
What is the current price of BCRX stock?
The current stock price of BCRX is 6.76 USD. The price decreased by -0.59% in the last trading session.
Does BIOCRYST PHARMACEUTICALS INC pay dividends?
BCRX does not pay a dividend.
How is the ChartMill rating for BIOCRYST PHARMACEUTICALS INC?
BCRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for BCRX stock?
15 analysts have analysed BCRX and the average price target is 22.21 USD. This implies a price increase of 228.6% is expected in the next year compared to the current price of 6.76.
What is the market capitalization of BCRX stock?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of 1.68B USD. This makes BCRX a Small Cap stock.
Can you provide the ownership details for BCRX stock?
You can find the ownership structure of BIOCRYST PHARMACEUTICALS INC (BCRX) on the Ownership tab.